2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 2/3
1
Phase 2
1
Status
Completed
4
Unknown
3
Terminated
1
Not yet recruiting
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
3
Sponsor
Cancer Type
Lymphoid
1
Dermatologic
1
Conditions
Uveal Melanoma
1
Substance Withdrawal Syndrome
1
Retinal Diseases
1
Opioid-Related Disorders
1
Myocardial Reperfusion Injury
1
Melanoma
1
Macular Degeneration
1
Lymphoma, Follicular
1
Choroid Diseases
1
Cardiotoxicity
1
Interventions
Cisplatin
517
Radiotherapy
378
Cyclophosphamide
368
Carboplatin
359
Capecitabine
342
Paclitaxel
337
Oxaliplatin
336
Gemcitabine
322
Docetaxel
317
Fluorouracil
290
Drug Therapy
276
Bevacizumab
248
apatinib
247
camrelizumab
219
Etoposide
201
Irinotecan
182
Doxorubicin
181
Leucovorin
163
Dexamethasone
161
pembrolizumab
153
Neoadjuvant Therapy
146
sintilimab
145
anlotinib
140
Blood Specimen Collection
140
Pemetrexed
138
Cytarabine
138
toripalimab
133
Surgical Procedures, Operative
131
Radiosurgery
131
S 1 (combination)
125
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Unknown
×
salicylhydroxamic acid
×
Clear all
NCT04850664
2021-08-06
CBOT-OUD
Evon Medics LLC
Phase 2
Unknown
190 enrolled
NCT02471885
2020-04-15
ERIC-ONC
University College, London
Phase NA
Unknown
128 enrolled
NCT00811200
2009-07-02
TORR
Leiden University Medical Center
Phase 2/3
Unknown
220 enrolled